Wockhardt · NSE: WOCKPHARMA · BSE: 532300
Q4 FY23 results · Jan–Mar 2023
Wockhardt reported revenue from operations of ₹678.00 crore (up 3.5% from Q4 FY22) and net loss of ₹237.00 crore for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 678.00 | 655.00 | +3.5% | 699.00 | −3.0% |
| Other income | 32.00 | 14.00 | +128.6% | 2.00 | 16x |
| Total income | 710.00 | 669.00 | +6.1% | 701.00 | +1.3% |
| Profit before tax | (193.00) | (347.00) | Loss narrowed | (105.00) | Loss widened |
| Net profit for the period | (237.00) | (311.00) | Loss narrowed | (102.00) | Loss widened |
| Attributable to shareholders of the company | (208.00) | (258.00) | Loss narrowed | (96.00) | Loss widened |
| EPS, basic (₹) | (14.37) | (21.20) | Loss narrowed | (6.62) | Loss widened |
| Net margin (%) | -35.0 | -47.5 | -14.6 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 291.00 | 474.00 | −38.6% | 282.00 | +3.2% |
| Other income | 29.00 | 22.00 | +31.8% | 18.00 | +61.1% |
| Total income | 320.00 | 496.00 | −35.5% | 300.00 | +6.7% |
| Profit before tax | (289.00) | 87.00 | Turned loss | (55.00) | Loss widened |
| Net profit for the period | (299.00) | 40.00 | Turned loss | (55.00) | Loss widened |
| EPS, basic (₹) | (20.80) | 3.24 | Turned loss | (3.81) | Loss widened |
| Net margin (%) | -102.7 | 8.4 | -19.5 |
Consolidated
- Filed with BSE
- 26 May 2023, 20:10 IST
- Board meeting
- 26 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 May 2023, 20:10 IST
- Board meeting
- 26 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE